CA2214451A1 - Systeme d'expression conditionnel - Google Patents

Systeme d'expression conditionnel Download PDF

Info

Publication number
CA2214451A1
CA2214451A1 CA002214451A CA2214451A CA2214451A1 CA 2214451 A1 CA2214451 A1 CA 2214451A1 CA 002214451 A CA002214451 A CA 002214451A CA 2214451 A CA2214451 A CA 2214451A CA 2214451 A1 CA2214451 A1 CA 2214451A1
Authority
CA
Canada
Prior art keywords
sequence
transactivator
domain
molecule
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002214451A
Other languages
English (en)
French (fr)
Inventor
Fabien Schweighoffer
Laurent Bracco
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2214451A1 publication Critical patent/CA2214451A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002214451A 1995-03-31 1996-03-29 Systeme d'expression conditionnel Abandoned CA2214451A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503841A FR2732348B1 (fr) 1995-03-31 1995-03-31 Systeme d'expression conditionnel
FR9503841 1995-03-31

Publications (1)

Publication Number Publication Date
CA2214451A1 true CA2214451A1 (fr) 1996-10-03

Family

ID=9477639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214451A Abandoned CA2214451A1 (fr) 1995-03-31 1996-03-29 Systeme d'expression conditionnel

Country Status (15)

Country Link
EP (1) EP0817845A1 (ko)
JP (1) JPH11503011A (ko)
KR (1) KR19980703439A (ko)
AU (1) AU716748B2 (ko)
BR (1) BR9607928A (ko)
CA (1) CA2214451A1 (ko)
CZ (1) CZ308097A3 (ko)
FR (1) FR2732348B1 (ko)
HU (1) HUP9801221A3 (ko)
IL (1) IL117713A0 (ko)
NO (1) NO974449D0 (ko)
SK (1) SK131197A3 (ko)
TW (1) TW496873B (ko)
WO (1) WO1996030512A1 (ko)
ZA (1) ZA962506B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872552A1 (en) * 1997-04-15 1998-10-21 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
WO1998055607A2 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
US6479653B1 (en) * 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
EP1040201A4 (en) * 1997-11-28 2001-11-21 Invitrogen Corp SINGLE CHAIN MONOCLONAL ANTIBODY FUSION AGENTS THAT REGULATE IN VIVO TRANSCRIPTION
FR2782732A1 (fr) * 1998-08-28 2000-03-03 Transgene Sa Systeme d'expression inductible
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
EP1242456B1 (en) 1999-11-18 2008-10-15 Oxford Biomedica (UK) Limited Scfv antibodies against disease associated molecules
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
WO2003045415A2 (en) * 2001-11-26 2003-06-05 University Health Network Self-assembling p53 peptides as gene delivery vehicles
AU2003229998A1 (en) 2002-05-10 2003-11-11 Medical Research Council Activation induced deaminase (aid)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2752788B2 (ja) * 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
CA2143326A1 (en) * 1992-08-26 1994-03-03 Guerard Byrne Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5650298A (en) * 1993-06-14 1997-07-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.

Also Published As

Publication number Publication date
BR9607928A (pt) 1998-06-09
MX9706928A (es) 1997-11-29
AU5402096A (en) 1996-10-16
SK131197A3 (en) 1998-05-06
HUP9801221A2 (hu) 1998-08-28
FR2732348B1 (fr) 1997-04-30
AU716748B2 (en) 2000-03-02
NO974449L (no) 1997-09-26
HUP9801221A3 (en) 1999-09-28
EP0817845A1 (fr) 1998-01-14
WO1996030512A1 (fr) 1996-10-03
CZ308097A3 (cs) 1998-01-14
TW496873B (en) 2002-08-01
ZA962506B (en) 1996-10-01
KR19980703439A (ko) 1998-11-05
NO974449D0 (no) 1997-09-26
IL117713A0 (en) 1996-07-23
JPH11503011A (ja) 1999-03-23
FR2732348A1 (fr) 1996-10-04

Similar Documents

Publication Publication Date Title
CA2214451A1 (fr) Systeme d'expression conditionnel
EP0848720B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
FR2722208A1 (fr) Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
FR2736915A1 (fr) Variants de la proteine p53 et utilisations therapeutiques
EP1049775B1 (fr) Proteine humaine btrcp
CA2250099A1 (fr) Sequences en amont du gene sm22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires
WO1998021327A1 (fr) Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes
CA2252529A1 (fr) Systeme d'expression derive du gene de la tyrosine hydroxylase
WO1996038556A2 (fr) Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse
EP0941243A1 (fr) Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
FR2720068A1 (fr) Protéines d'interaction avec la protéine Nef du virus HIV1, séquences d'acides nucléiques codant pour ces protéines et leur utilisation pour le criblage d'agents anti-viraux anti-HIV.
MXPA97006928A (es) Sistema de expresion condicional
CA2343922A1 (fr) Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
Isserlin Syntrophin expression and interacting protein partners in the central nervous system
FR2783839A1 (fr) Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued